167 related articles for article (PubMed ID: 22926639)
1. Molecular-targeted therapies for ovarian cancer.
Kigawa J
Int J Clin Oncol; 2012 Oct; 17(5):423. PubMed ID: 22926639
[No Abstract] [Full Text] [Related]
2. Targeted therapy in ovarian cancer.
Lim HJ; Ledger W
Womens Health (Lond); 2016 Jun; 12(3):363-78. PubMed ID: 27215391
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies for treatment of recurrent ovarian cancer.
Grisham RN; Hyman DM; Iyer G
Clin Adv Hematol Oncol; 2014 Mar; 12(3):158-62. PubMed ID: 24927263
[TBL] [Abstract][Full Text] [Related]
4. [Impact of molecular classification on clinical management of ovarian cancer].
Hasegawa K
Gan To Kagaku Ryoho; 2015 Feb; 42(2):166-8. PubMed ID: 25834913
[No Abstract] [Full Text] [Related]
5. Ovarian cancer: how can resistance to chemotherapy be tackled?
Karakashev S; Aird KM
Future Oncol; 2017 Dec; 13(30):2737-2739. PubMed ID: 29182383
[No Abstract] [Full Text] [Related]
6. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
[TBL] [Abstract][Full Text] [Related]
7. [Future Perspectives in Treatment of Ovarian Cancer].
Fujiwara K
Gan To Kagaku Ryoho; 2016 Feb; 43(2):174-5. PubMed ID: 27093726
[No Abstract] [Full Text] [Related]
8. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
[TBL] [Abstract][Full Text] [Related]
9. Successes and limitations of targeted cancer therapy in ovarian cancer.
Damia G; Sessa C
Prog Tumor Res; 2014; 41():89-97. PubMed ID: 24727989
[TBL] [Abstract][Full Text] [Related]
10. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer.
Ledermann JA; Marth C; Carey MS; Birrer M; Bowtell DD; Kaye S; McNeish I; Oza A; Scambia G; Rustin G; Stehman FB; Gershenson D; Thomas G; Berns E; Casado A; Ottevanger N; Hilpert F; Kim BG; Okamoto A; Bacon M; Kitchener H; Stuart GC;
Int J Gynecol Cancer; 2011 May; 21(4):763-70. PubMed ID: 21543938
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of ovarian clear cell carcinoma].
Mabuchi S; Takahashi R; Sasano T; Kuroda H; Kimura T
Gan To Kagaku Ryoho; 2015 Feb; 42(2):174-8. PubMed ID: 25834915
[No Abstract] [Full Text] [Related]
12. Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
Jacot W; Theillet C; Guiu S; Lamy PJ
Future Oncol; 2015; 11(4):557-9. PubMed ID: 25686112
[No Abstract] [Full Text] [Related]
13. Targeted Therapy in Ovarian Cancer. A Comprehensive Systematic Review of Literature.
Diab Y; Muallem MZ
Anticancer Res; 2017 Jun; 37(6):2809-2815. PubMed ID: 28551615
[TBL] [Abstract][Full Text] [Related]
14. New drugs in ovarian cancer.
Fleming GF
Clin Adv Hematol Oncol; 2015 Apr; 13(4):223-5. PubMed ID: 26352580
[No Abstract] [Full Text] [Related]
15. PARP inhibitors in ovarian and other cancers.
Plummer R
Clin Adv Hematol Oncol; 2015 May; 13(5):285-7. PubMed ID: 26352770
[No Abstract] [Full Text] [Related]
16. Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
Ray-Coquard I; Vanacker H; Le Saux O; Tredan O
EBioMedicine; 2020 Nov; 61():103046. PubMed ID: 33038760
[No Abstract] [Full Text] [Related]
17. [Low-grade serous, mucinous carcinoma].
Nakayama K; Kyo S
Gan To Kagaku Ryoho; 2015 Feb; 42(2):179-82. PubMed ID: 25834916
[No Abstract] [Full Text] [Related]
18. Recurrent ovarian cancer.
Pujade-Lauraine E; Combe P
Ann Oncol; 2016 Apr; 27 Suppl 1():i63-i65. PubMed ID: 27141075
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer relapse: From the latest scientific evidence to the best practice.
Luvero D; Plotti F; Aloisia A; Montera R; Terranova C; Carlo De Cicco Nardone ; Scaletta G; Lopez S; Miranda A; Capriglione S; Gatti A; Pierluigi Benedetti Panici ; Angioli R
Crit Rev Oncol Hematol; 2019 Aug; 140():28-38. PubMed ID: 31176270
[TBL] [Abstract][Full Text] [Related]
20. E2F1 as a molecular drug target in ovarian cancer.
Farra R; Dapas B; Grassi M; Benedetti F; Grassi G
Expert Opin Ther Targets; 2019 Mar; 23(3):161-164. PubMed ID: 30724632
[No Abstract] [Full Text] [Related]
[Next] [New Search]
